Stanislav S W, Crismon M L, Childs N L
Brown Schools Rehabilitation Center, Austin, Texas 78712, USA.
Biol Psychiatry. 1998 Apr 15;43(8):619-21. doi: 10.1016/s0006-3223(97)00405-8.
This pilot study was conducted to determine if aggressive, post brain-injured patients have abnormal glucose metabolism or abnormal CSF monoamine metabolite concentrations as compared with non-aggressive, post brain-injured controls.
Subjects with a history of traumatic brain injury underwent a lumbar puncture and glucose tolerance test after a three-week medication wash-out period. Monoamine metabolite concentrations and glucose nadirs were compared between aggressive and control subjects.
There were no statistical differences between the aggressive (n = 4) and control (n = 6) group with respect to age (28.5 +/- 15.7 versus 28.0 +/- 10.8), weight (72.5 kg +/- 14.1 versus 67.7 kg +/- 10.1) or number of months since brain injury (31.8 +/- 26.1 versus 33.3 +/- 23.3). There were no significant differences between the two groups in glucose nadirs following oral glucose challenge or in levels of CSF monoamine metabolite concentrations of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), or 3-methoxy-4-hydroxyphenylglycol (MHPG), although a trend toward significance was noted between the MHPG groups (higher MHPG within aggressive group).
The preliminary data suggest that glucose metabolism and CSF monoamine metabolite concentrations do not differ significantly from aggressive subjects to controls in persons with brain injury. Follow-up prospective studies with larger sample sizes are needed to evaluate these preliminary findings.
本试点研究旨在确定与非攻击性脑损伤后对照组相比,攻击性脑损伤后患者是否存在葡萄糖代谢异常或脑脊液单胺代谢物浓度异常。
有创伤性脑损伤病史的受试者在停药三周后接受腰椎穿刺和葡萄糖耐量试验。比较攻击性受试者和对照组之间的单胺代谢物浓度和葡萄糖最低点。
攻击性组(n = 4)和对照组(n = 6)在年龄(28.5 +/- 15.7对28.0 +/- 10.8)、体重(72.5 kg +/- 14.1对67.7 kg +/- 10.1)或脑损伤后的月数(31.8 +/- 26.1对33.3 +/- 23.3)方面无统计学差异。口服葡萄糖激发后两组的葡萄糖最低点或脑脊液单胺代谢物5-羟吲哚乙酸(5-HIAA)、高香草酸(HVA)或3-甲氧基-4-羟基苯乙二醇(MHPG)的浓度水平均无显著差异,尽管MHPG组之间存在显著趋势(攻击性组内MHPG较高)。
初步数据表明,脑损伤患者中,攻击性受试者与对照组在葡萄糖代谢和脑脊液单胺代谢物浓度方面无显著差异。需要进行更大样本量的后续前瞻性研究来评估这些初步发现。